



## Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024

March 5, 2024

CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, announced today that it will be presenting preclinical data on its lead program IMM-1-104 at the American Association for Cancer Research (AACR) annual meeting, held April 5-10 in San Diego, California.

Details for the poster presentation are as follows:

**Title: Activity of IMM-1-104 alone or in combination with chemotherapy in RAS-altered pancreatic cancer models**

Date and Time: Tuesday Apr 9, 2024, 9:00 AM - 12:30 PM PT

Poster Session: In Vivo Imaging and Humanized Models

Location: Poster Section 9, Poster Board #19

Abstract Number: 4195

The abstract is available on the AACR Online Program and will be published in the online *Proceedings of the AACR*. Following presentation, the poster will be available on the [publications](#) section of Immuneering's website.

### About Immuneering Corporation

Immuneering is a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy. The Company aims to achieve universal activity through deep cyclic inhibition of the MAPK pathway, impacting cancer cells while sparing healthy cells. Immuneering's lead product candidate, IMM-1-104, is an oral, once-daily deep cyclic inhibitor currently in a Phase 1/2a study in patients with advanced solid tumors harboring RAS mutations. IMM-6-415 is an oral, twice-daily deep cyclic inhibitor and will be evaluated in a Phase 1/2a study in patients with advanced solid tumors harboring RAS or RAF mutations. The company's development pipeline also includes several early-stage programs. For more information, please visit [www.immuneering.com](http://www.immuneering.com).

### Media Contact:

Gina Nugent

Nugent Communications

617-460-3579

[gina@nugentcommunications.com](mailto:gina@nugentcommunications.com)

### Investor Contacts:

Laurence Watts

Gilmartin Group

619-916-7620

[laurence@gilmartinir.com](mailto:laurence@gilmartinir.com)

or

Kiki Patel, PharmD

Gilmartin Group

332-895-3225

[kiki@gilmartinir.com](mailto:kiki@gilmartinir.com)